The Medicines Company Stock

Equities

MDCO

US5846881051

Pharmaceuticals

Delayed Nasdaq 5-day change 1st Jan Change
- USD -.--% Intraday chart for The Medicines Company +0.14% -0.05%

Valuation: The Medicines Company

Capitalization 6.79B 6.46B 5.99B 5.33B 9.62B 576B 10.66B 74.59B 27.53B 237B 25.49B 24.94B 1,033B P/E ratio 2017
-2.79x
P/E ratio 2018 -11.4x
Enterprise value 7.34B 6.99B 6.48B 5.76B 10.4B 623B 11.52B 80.65B 29.77B 256B 27.57B 26.97B 1,117B EV / Sales 2017
55.1x
EV / Sales 2018 319x
Free-Float
-
Yield 2017 *
-
Yield 2018 -
More valuation ratios * Estimated data
Director TitleAgeSince
Investor Relations Contact - -
General Counsel 47 -
Manager TitleAgeSince
Director/Board Member 81 -
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-.--%+0.14% - - 6.79B
+0.18%+0.08%+46.46%+138.23%51.08B
+0.32%-3.64%+54.93%+115.51%31.33B
-0.18%-2.67%+40.01% - 18.98B
-0.94%-3.48%+19.37%+62.68%13.98B
-0.84%-0.04%+52.56%+110.68%11.65B
-.--%-1.95% - - 5.73B
-0.03%-2.16%-34.00%-37.39%5.32B
-0.03%-1.59%+4.45%+20.22%5.23B
+1.88%-0.32%+93.81%+203.82%5.04B
Average +0.03%-0.93%+34.70%+87.68% 15.51B
Weighted average by Cap. +0.00%-0.80%+42.43%+111.45%
See all sector performances

Financials

2017 2018
Net sales 44.79M 42.63M 39.51M 35.14M 63.43M 3.8B 70.3M 492M 182M 1.56B 168M 165M 6.81B 6.14M 5.84M 5.41M 4.82M 8.69M 521M 9.63M 67.42M 24.89M 214M 23.04M 22.55M 933M
Net income -708M -674M -625M -556M -1B -60.11B -1.11B -7.78B -2.87B -24.68B -2.66B -2.6B -108B -123M -117M -109M -96.62M -174M -10.45B -193M -1.35B -499M -4.29B -462M -452M -18.73B
Net Debt 498M 474M 439M 391M 705M 42.25B 781M 5.47B 2.02B 17.35B 1.87B 1.83B 75.7B 552M 525M 487M 433M 781M 46.83B 866M 6.06B 2.24B 19.23B 2.07B 2.03B 83.91B
More financial data * Estimated data
Logo The Medicines Company
The Medicines Company is a global biopharmaceutical company. The Company is focused on the development of inclisiran, a twice-yearly therapy that allows administration during patients routine visits to their healthcare professionals and potentially contributes to improved patient adherence and sustained lower LDL-C levels. The Company is a subsidiary of Novartis AG.
Employees
0
More about the company